BioCentury | Jun 5, 2020
Finance

Founding investors MPM, F2 back Cullinan’s asset-centric approach with $98.5M series B

...New Modality Search Engine” ). Its other clinical program is a small molecule inhibitor of EBNA1...
...The main difference from Cullinan, said Hughes, is that it isn’t restricted to oncology. Targets EBNA1...
...receptor FLT3 (CD135) - FMS-like tyrosine kinase 3 ligand Lauren Martz, Senior Editor Taiho Ventures LLC Cullinan Oncology LLC Epstein-Barr virus nuclear antigen 1 (EBNA1) FMS-like...
BioCentury | Dec 20, 2019

An inhibitor of viral latency for imaging, treating EBV-associated cancers

...DISEASE CATEGORY: Cancer INDICATION: Nasopharyngeal cancer; lymphoma A peptide-based compound that inhibits EBNA1, which promotes Epstein-Barr...
...intensities corresponded with EBNA1 protein levels. In a xenograft mouse model of nasopharyngeal cancer, the EBNA1...
...it could be used as a marker of therapeutic response to an EBNA1 inhibitor. TARGET/MARKER/PATHWAY: Epstein-Barr virus nuclear antigen 1 (EBNA1)...
BioCentury | Mar 13, 2019
Distillery Therapeutics

EBNA1 inhibitors for EBV-dependent cancers

...In vitro , cell culture and mouse studies identified two prodrugs of phenylacetylenyl benzoic acid-based EBNA1...
...screening hits, followed by in vitro testing, yielded two phenylacetylenyl benzoic acid-based compounds that bound EBNA1...
...compared with any treatment alone. Next steps could include PK/PD studies of the prodrugs. TARGET/MARKER/PATHWAY: Epstein-Barr virus nuclear antigen 1 (EBNA1)...
BioCentury | Jan 13, 2018
Finance

JPM jolt

...multiple sclerosis. Data are expected in 1H19. ATA188 comprises allogeneic Epstein-Barr virus-specific T cells targeting Epstein-Barr virus nuclear antigen 1 (EBNA1)...
BioCentury | Dec 1, 2017
Clinical News

QIMR reports updated Phase I data for MS candidate

...allogeneic ATA188, under a 2015 deal. Autologous ATA190 comprises autologous Epstein-Barr virus-specific T cells targeting Epstein-Barr virus nuclear antigen 1 (EBNA1)...
...Epstein-Barr virus nuclear antigen 1 (EBNA1); Epstein-Barr virus latent membrane protein 1 (LMP1) Description: Autologous Epstein-Barr virus-specific T cells targeting EBNA1...
BioCentury | Mar 31, 2014
Clinical News

MVA-EBNA/LMP2 vaccine: Phase Ib started

...vector encoding the gene for the Epstein-Barr virus (EBV) antigen Epstein-Barr nuclear antigen 1 ( EBNA1...
BioCentury | Mar 29, 2012
Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Lymphoma Epstein-Barr nuclear antigen 3B (EBNA3B) Mouse and patient sample studies suggest increasing EBNA3B signaling could help prevent Epstein-Barr virus (EBV)-associated...
BioCentury | Jun 8, 1998
Clinical News

Trinity regulatory update

The FDA granted marketing clearance to EBNA-1 IgM and EA-D IgG, TRIBY's markers that detect the presence of the Epstein-Barr virus. Wampole Laboratories (Cranbury, N.J.) will distribute the products in the U.S. Trinity Biotech plc...
BioCentury | Sep 13, 1993
Clinical News

Isis regulatory update

ISIP said U.S. Patent No. 5,242,906, to which it has an exclusive license, issued to the University of North Carolina at Chapel Hill covering antisense oligonucleotide or oligonucleotide analogs that inhibit expression of the EBNA-1...
Items per page:
1 - 9 of 9